Logo Pacira BioSciences, Inc.

Pacira BioSciences, Inc. (PCRX) stock: analyst price target and their real reliability

Live quote · data updated Aug 28, 2026
Pacira BioSciences, Inc. · Health Care · ref. ETF XLV · 90 calls · price $25.83
🏆JPI 2026 portfoliosSee tracking →
What the company does: Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.

📈 Pacira BioSciences, Inc. (PCRX) stock price

$25.83-3.8% over range
Aug 28, 25low $19.16 · high $27.62Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
50% recommend buying · 4 analysts
📊 JPI status : Pacira BioSciences, Inc. is no longer in our current JPI rankings, but appeared in the past (2025, 2024, 2016) — its upside may be behind it. See the stocks picked in 2025 →

🎯 PCRX price target & analyst consensusprice $25.83

The price target · all analysts combined (4 targets)
Highest target · 1 firm of 4$38+47.1%
Median target · of 4 targets$29+12.3%
Lowest target · 2 firms of 4$25-3.2%
Current price$25.83
Where these 4 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 250% $33 ↔ $38
Below 250% $25
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: HC Wainwright & Co.61% of its targets hit on this sector (321 calls tested). It aims for $38 (+47 %), call made on July 2, 2026, maturing on July 2, 2027 (57 d ago).

The 1 reliable analyst $38+47 %
The 3 other firms $25-3.2 %
How to read it: the 1 reliable firms are not filtered by optimism — 1 aim above the price, 0 below, hence their $38 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 4 ratings (last 6 months)
Strong Buy00%
Buy250%
Hold250%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Pacira BioSciences, Inc.? The JPI assistant answers using our backtest data.

🔎 Detailed analyses

🏛️ Which US Congress members hold Pacira BioSciences, Inc. (PCRX)?

1 Congress member has disclosed PCRX buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Tom Malinowski · 18%
→ Full members ranking (who beats the market)

✅ Historical analyst reliability on PCRX

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm % right i Gain vs sector i Calls i
SVB Leerink 100% +84.2% 2
B of A Securities  100% +37.2% 2
Jefferies  71% +57.3% 14
Wedbush  50% +53.8% 10
Northland Capital Markets  50% +50.2% 2
Raymond James  50% -16.4% 2
Needham  37% -2.6% 27
Piper Sandler  33% +16.6% 9
Truist Securities  33% -46.4% 3
HC Wainwright & Co.  32% -6.7% 22
See the other 6 firms
JP Morgan  0% -52.7% 2
JMP Securities 0% -25.1% 3
Mizuho  0% -20.2% 2
RBC Capital  12% -31.5% 8
Barclays  27% +14.6% 15
Canaccord Genuity  29% -17.6% 7

📊 What $1,000 invested in Pacira BioSciences, Inc. would be worth › open the full page

In short — $1,000 invested in Pacira BioSciences, Inc. 10 years ago would be worth $326 today, i.e. -11%/yr on average. Best year: 2017 (+41%), worst: 2016 (-58%). Price performance, excluding dividends.

If I'd invested $1,000 in Pacira BioSciences, Inc.

InvestmentWorth todayGain
1 years ago$1,327+33%
3 years ago$648-35%
5 years ago$418-58%
→ See Pacira BioSciences, Inc.'s full return history + gain calculator

Return by year (Pacira BioSciences, Inc.)

YearReturn$1,000 invested at year start
2026 (YTD)-3%$966 (-3%)
2025+37%$1,327 (+33%)
2024-44%$741 (-26%)
→ See Pacira BioSciences, Inc.'s full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Pacira BioSciences, Inc.

Loading news…

📋 All analyst calls on PCRX

RBC Capital 
Aug 5, 26
■ Sector Perform neutral · not a buy · 🎯$25
Price at call : $25.58 — gap to target -2%
Today : $25.83 — gap to target -3%
🎯 on PCRX : 50% (2 calls matureds) · 📊 on Health : 30.7% · -10.7% (166 calls)
in progress (365j)
matures : Aug 5, 27
Needham 
Aug 5, 26
▲ Buy · 🎯$33
Price at call : $24.87 — upside +33%
Today : $25.83 — upside +28%
🎯 on PCRX : 50% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
in progress (365j)
matures : Aug 5, 27
▲ Buy · 🎯$38
Price at call : $25.03 — upside +52%
Today : $25.83 — upside +47%
🎯 on PCRX : 25% (12 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
in progress (365j)
matures : Jul 1, 27
RBC Capital 
May 1, 26
■ Sector Perform neutral · not a buy · 🎯$24
Price at call : $24.69 — gap to target -3%
Today : $25.83 — gap to target -7%
🎯 on PCRX : 50% (2 calls matureds) · 📊 on Health : 30.7% · -10.7% (166 calls)
in progress (365j)
matures : May 1, 27
Needham 
May 1, 26
▲ Buy · 🎯$32
Price at call : $24.44 — upside +31%
Today : $25.83 — upside +24%
🎯 on PCRX : 50% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
in progress (365j)
matures : May 1, 27
Barclays 
Mar 26, 26
■ Equal-Weight neutral · not a buy · 🎯$25
Price at call : $23.31 — gap to target +7%
Today : $25.83 — gap to target -3%
🎯 on PCRX : 8% (12 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : Mar 26, 27
▲ Buy · 🎯$38
Price at call : $23.53 — upside +61%
Today : $25.83 — upside +47%
🎯 on PCRX : 25% (12 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
in progress (365j)
matures : Jan 9, 27
Needham 
Jan 9, 26
▲ Buy · 🎯$30
Price at call : $23.53 — upside +27%
Today : $25.83 — upside +16%
🎯 on PCRX : 50% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
in progress (365j)
matures : Jan 9, 27
See the other 82 calls, newest to oldest
Barclays 
Dec 9, 25
■ Equal-Weight neutral · not a buy · 🎯$27
Price at call : $25.18 — gap to target +7%
Today : $25.83 — gap to target +5%
🎯 on PCRX : 8% (12 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : Dec 9, 26
▲ Buy · 🎯$28
Price at call : $23.07 — upside +21%
Today : $25.83 — upside +8%
🎯 on PCRX : 50% (2 calls matureds) · 📊 on Health : 37.6% · -0.8% (165 calls)
in progress (365j)
matures : Nov 7, 26
Needham 
May 9, 25
▲ Buy · 🎯$30
Price at call : $25.12 — upside +19%
Today : $25.83 — upside +16%
Expected +19% · Actual -9% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
-9.5%
stock -9% · XLV +8%
matured May 9, 26
Needham 
Apr 8, 25
▲ Buy · 🎯$32
Price at call : $26.27 — upside +22%
Today : $25.83 — upside +24%
Expected +22% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
-11.5%
stock -12% · XLV +13%
matured Apr 8, 26
▲ Buy · 🎯$65
Price at call : $26.27 — upside +147%
Today : $25.83 — upside +152%
Expected +147% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 25% (12 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
-11.5%
stock -12% · XLV +13%
matured Apr 8, 26
Barclays 
Mar 1, 25
▲ Overweight · 🎯$24
Price at call : $22.96 — upside +5%
Today : $25.83 — upside -7%
Expected +5% · Actual -7% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 8% (12 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-7.3%
stock -7% · XLV +6%
matured Mar 1, 26
Needham 
Feb 28, 25
▲ Buy · 🎯$32
Price at call : $24.05 — upside +33%
Today : $25.83 — upside +24%
Expected +33% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
-11.5%
stock -12% · XLV +6%
matured Feb 28, 26
▲ Buy · 🎯$70
Price at call : $24.05 — upside +191%
Today : $25.83 — upside +171%
Expected +191% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 25% (12 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
-11.5%
stock -12% · XLV +6%
matured Feb 28, 26
■ Hold neutral · not a buy · 🎯$25
Price at call : $26.33 — gap to target -5%
Today : $25.83 — gap to target -3%
🎯 on PCRX : 50% (2 calls matureds) · 📊 on Health : 37.6% · -0.8% (165 calls)
in progress (365j)
matures : Jan 30, 26
RBC Capital 
Jan 14, 25
■ Sector Perform neutral · not a buy · 🎯$18
Price at call : $21.88 — gap to target -18%
Today : $25.83 — gap to target -30%
🎯 on PCRX : 50% (2 calls matureds) · 📊 on Health : 30.7% · -10.7% (166 calls)
in progress (365j)
matures : Jan 14, 26
Needham 
Jan 13, 25
▲ Buy · 🎯$30
Price at call : $21.13 — upside +42%
Today : $25.83 — upside +16%
Expected +42% · Actual +2% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
+2.2%
stock +2% · XLV +11%
matured Jan 13, 26
Needham 
Dec 17, 24
▲ Buy · 🎯$30
Price at call : $19.83 — upside +51%
Today : $25.83 — upside +16%
Expected +51% · Actual +34% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 50% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
+33.9%
stock +34% · XLV +10%
matured Dec 17, 25
▲ Buy · 🎯$39
Price at call : $19.09 — upside +104%
Today : $25.83 — upside +51%
Expected +104% · Actual +26% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 25% (12 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
+25.6%
stock +26% · XLV +5%
matured Dec 4, 25
Barclays 
Nov 12, 24
■ Equal-Weight neutral · not a buy · 🎯$17
Price at call : $16.45 — gap to target +3%
Today : $25.83 — gap to target -34%
🎯 on PCRX : 8% (12 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : Nov 12, 25
Needham 
Nov 8, 24
▲ Buy · 🎯$22
Price at call : $17.24 — upside +28%
Today : $25.83 — upside -15%
Expected +28% · Actual +34% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 50% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
+33.8%
stock +34% · XLV -2%
matured Nov 8, 25
RBC Capital 
Nov 7, 24
■ Sector Perform neutral · not a buy · 🎯$16
Price at call : $17.24 — gap to target -7%
Today : $25.83 — gap to target -38%
🎯 on PCRX : 50% (2 calls matureds) · 📊 on Health : 30.7% · -10.7% (166 calls)
in progress (365j)
matures : Nov 7, 25
RBC Capital 
Oct 4, 24
■ Sector Perform neutral · not a buy · 🎯$15
Price at call : $15.99 — gap to target -6%
Today : $25.83 — gap to target -42%
🎯 on PCRX : 50% (2 calls matureds) · 📊 on Health : 30.7% · -10.7% (166 calls)
in progress (365j)
matures : Oct 4, 25
Jefferies 
Sep 24, 24
▲ Buy · 🎯$18
Price at call : $13.91 — upside +29%
Today : $25.83 — upside -30%
Expected +29% · Actual +84% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 67% (12 calls matureds) · 📊 on Health : 50% · +9.9% (136 calls)
+84.4%
stock +84% · XLV -12%
matured Sep 24, 25
▼ Sell · 🎯$8
Price at call : $12.47 — upside -36%
Today : $25.83 — upside -69%
Expected -36% · Actual +100% · Reason (≤ −15%) : ✗ No
🎯 on PCRX : 50% (2 calls matureds) · 📊 on Health : 37.6% · -0.8% (165 calls)
-100.4%
stock +100% · XLV -12%
matured Aug 13, 25
RBC Capital 
Aug 12, 24
■ Sector Perform neutral · not a buy · 🎯$14
Price at call : $12.4 — gap to target +13%
Today : $25.83 — gap to target -46%
🎯 on PCRX : 50% (2 calls matureds) · 📊 on Health : 30.7% · -10.7% (166 calls)
in progress (365j)
matures : Aug 12, 25
▲ Buy · 🎯$39
Price at call : $12.29 — upside +217%
Today : $25.83 — upside +51%
Expected +217% · Actual +102% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 25% (12 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
+101.9%
stock +102% · XLV -12%
matured Aug 12, 25
Needham 
Aug 12, 24
▲ Buy · 🎯$22
Price at call : $12.29 — upside +79%
Today : $25.83 — upside -15%
Expected +79% · Actual +102% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 50% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
+101.9%
stock +102% · XLV -12%
matured Aug 12, 25
JP Morgan 
Aug 12, 24
▼ Underweight · 🎯$10
Price at call : $12.29 — upside -19%
Today : $25.83 — upside -61%
Expected -19% · Actual +102% · Reason (≤ −15%) : ✗ No
🎯 on PCRX : 0% (1 call matured) · 📊 on Health : 49.3% · +6.9% (146 calls)
-101.9%
stock +102% · XLV -12%
matured Aug 12, 25
Jefferies 
Aug 1, 24
▲ Buy · 🎯$30
Price at call : $20.75 — upside +45%
Today : $25.83 — upside +16%
Expected +45% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 67% (12 calls matureds) · 📊 on Health : 50% · +9.9% (136 calls)
+6.4%
stock +6% · XLV -13%
matured Aug 1, 25
Raymond James 
Jul 31, 24
▲ Outperform · 🎯$37
Price at call : $20.75 — upside +78%
Today : $25.83 — upside +43%
Expected +78% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (2 calls matureds) · 📊 on Health : 39.9% · -2.0% (218 calls)
+6.4%
stock +6% · XLV -13%
matured Jul 31, 25
RBC Capital 
Jul 31, 24
▲ Outperform · 🎯$37
Price at call : $20.75 — upside +78%
Today : $25.83 — upside +43%
Expected +78% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (2 calls matureds) · 📊 on Health : 30.7% · -10.7% (166 calls)
+6.4%
stock +6% · XLV -13%
matured Jul 31, 25
Needham 
Jul 31, 24
▲ Buy · 🎯$43
Price at call : $20.65 — upside +108%
Today : $25.83 — upside +66%
Expected +108% · Actual +2% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
+2.1%
stock +2% · XLV -13%
matured Jul 31, 25
▲ Buy · 🎯$30
Price at call : $20.03 — upside +50%
Today : $25.83 — upside +16%
Expected +50% · Actual +10% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (2 calls matureds) · 📊 on Health : 37.6% · -0.8% (165 calls)
+10.1%
stock +10% · XLV -10%
matured Jul 25, 25
Piper Sandler 
Jul 3, 24
▲ Overweight · 🎯$42
Price at call : $21.06 — upside +99%
Today : $25.83 — upside +63%
Expected +99% · Actual +10% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 100% (1 call matured) · 📊 on Health : 45.8% · +6.9% (249 calls)
+10.3%
stock +10% · XLV -7%
matured Jul 3, 25
Barclays 
Jul 3, 24
■ Equal-Weight neutral · not a buy · 🎯$25
Price at call : $21.66 — gap to target +15%
Today : $25.83 — gap to target -3%
🎯 on PCRX : 8% (12 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
in progress (365j)
matures : Jul 3, 25
Needham 
Jul 2, 24
▲ Buy · 🎯$43
Price at call : $21.66 — upside +99%
Today : $25.83 — upside +66%
Expected +99% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
+7.2%
stock +7% · XLV -5%
matured Jul 2, 25
▲ Buy · 🎯$57
Price at call : $21.66 — upside +163%
Today : $25.83 — upside +121%
Expected +163% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 25% (12 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
+7.2%
stock +7% · XLV -5%
matured Jul 2, 25
▲ Buy · 🎯$57
Price at call : $29.86 — upside +91%
Today : $25.83 — upside +121%
Expected +91% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 25% (12 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
-15.9%
stock -16% · XLV -7%
matured May 8, 25
Barclays 
May 8, 24
▲ Overweight · 🎯$38
Price at call : $29.86 — upside +27%
Today : $25.83 — upside +47%
Expected +27% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 8% (12 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-15.9%
stock -16% · XLV -7%
matured May 8, 25
Needham 
May 8, 24
▲ Buy · 🎯$43
Price at call : $29.65 — upside +45%
Today : $25.83 — upside +66%
Expected +45% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
-16.0%
stock -16% · XLV -6%
matured May 8, 25
Needham 
Apr 9, 24
▲ Buy · 🎯$45
Price at call : $28.52 — upside +58%
Today : $25.83 — upside +74%
Expected +58% · Actual -9% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
-9.4%
stock -9% · XLV -3%
matured Apr 9, 25
▲ Buy · 🎯$57
Price at call : $29.2 — upside +95%
Today : $25.83 — upside +121%
Expected +95% · Actual -19% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 25% (12 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
-19.4%
stock -19% · XLV +1%
matured Mar 4, 25
RBC Capital 
Mar 1, 24
▲ Outperform · 🎯$45
Price at call : $29.2 — upside +54%
Today : $25.83 — upside +74%
Expected +54% · Actual -21% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (2 calls matureds) · 📊 on Health : 30.7% · -10.7% (166 calls)
-21.4%
stock -21% · XLV +2%
matured Mar 1, 25
Needham 
Mar 1, 24
▲ Buy · 🎯$45
Price at call : $28.86 — upside +56%
Today : $25.83 — upside +74%
Expected +56% · Actual -20% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
-20.4%
stock -20% · XLV +2%
matured Mar 1, 25
Wedbush 
Feb 8, 24
▲ Outperform · 🎯$57
Price at call : $27.7 — upside +106%
Today : $25.83 — upside +121%
Expected +106% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (10 calls matureds) · 📊 on Health : 35.8% · +3.2% (53 calls)
-5.8%
stock -6% · XLV +2%
matured Feb 7, 25
Raymond James 
Dec 20, 23
▲ Outperform · 🎯$42
Price at call : $32.21 — upside +30%
Today : $25.83 — upside +63%
Expected +30% · Actual -39% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (2 calls matureds) · 📊 on Health : 39.9% · -2.0% (218 calls)
-39.2%
stock -39% · XLV +3%
matured Dec 19, 24
▲ Buy · 🎯$57
Price at call : $30.74 — upside +85%
Today : $25.83 — upside +121%
Expected +85% · Actual -44% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 25% (12 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
-43.8%
stock -44% · XLV +15%
matured Nov 5, 24
Barclays 
Oct 23, 23
▲ Overweight · 🎯$57
Price at call : $28.22 — upside +102%
Today : $25.83 — upside +121%
Expected +102% · Actual -38% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 8% (12 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-38.4%
stock -38% · XLV +18%
matured Oct 22, 24
▲ Buy · 🎯$63
Price at call : $38.75 — upside +63%
Today : $25.83 — upside +144%
Expected +63% · Actual -45% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 25% (12 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
-45.1%
stock -45% · XLV +14%
matured Aug 2, 24
▲ Buy · 🎯$68
Price at call : $37.26 — upside +83%
Today : $25.83 — upside +163%
Expected +83% · Actual -42% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 25% (12 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
-41.6%
stock -42% · XLV +14%
matured Jul 12, 24
▲ Buy · 🎯$71
Price at call : $43.14 — upside +65%
Today : $25.83 — upside +175%
Expected +65% · Actual -37% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 25% (12 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
-36.9%
stock -37% · XLV +6%
matured May 3, 24
▲ Buy · 🎯$71
Price at call : $43.38 — upside +64%
Today : $25.83 — upside +175%
Expected +64% · Actual -31% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 25% (12 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
-31.5%
stock -31% · XLV +14%
matured Feb 29, 24
Wedbush 
Feb 28, 22
▲ Outperform · 🎯$94
Price at call : $66.69 — upside +41%
Today : $25.83 — upside +264%
Expected +41% · Actual -36% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (10 calls matureds) · 📊 on Health : 35.8% · +3.2% (53 calls)
-36.2%
stock -36% · XLV -2%
matured Feb 28, 23
Barclays 
Jan 19, 22
▲ Overweight · 🎯$96
Price at call : $64.26 — upside +49%
Today : $25.83 — upside +272%
Expected +49% · Actual -42% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 8% (12 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-42.3%
stock -42% · XLV +1%
matured Jan 19, 23
Barclays 
Nov 5, 21
▲ Overweight · 🎯$92
Price at call : $58.95 — upside +56%
Today : $25.83 — upside +256%
Expected +56% · Actual -15% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 8% (12 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-14.6%
stock -15% · XLV -1%
matured Nov 5, 22
Barclays 
Oct 1, 21
▲ Overweight · 🎯$91
Price at call : $56.98 — upside +60%
Today : $25.83 — upside +252%
Expected +60% · Actual -3% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 8% (12 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-3.4%
stock -3% · XLV -3%
matured Oct 1, 22
Wedbush 
Nov 2, 20
▲ Outperform · 🎯$83
Price at call : $52.57 — upside +58%
Today : $25.83 — upside +221%
Expected +58% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (10 calls matureds) · 📊 on Health : 35.8% · +3.2% (53 calls)
+7.3%
stock +7% · XLV +31%
matured Nov 2, 21
Jefferies 
Jul 10, 20
▲ Buy · 🎯$69
Price at call : $57.8 — upside +19%
Today : $25.83 — upside +167%
Expected +19% · Actual -2% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 67% (12 calls matureds) · 📊 on Health : 50% · +9.9% (136 calls)
-1.7%
stock -2% · XLV +28%
matured Jul 10, 21
Barclays 
Jun 11, 19
▲ Overweight · 🎯$52
Price at call : $43.06 — upside +21%
Today : $25.83 — upside +101%
Expected +21% · Actual +9% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 8% (12 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
+8.6%
stock +9% · XLV +13%
matured Jun 10, 20
Barclays 
Aug 6, 18
▲ Overweight · 🎯$50
Price at call : $45.2 — upside +11%
Today : $25.83 — upside +94%
Expected +11% · Actual -4% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 8% (12 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-3.5%
stock -4% · XLV +0%
matured Aug 6, 19
Wedbush 
Aug 6, 18
▲ Outperform · 🎯$85
Price at call : $45.2 — upside +88%
Today : $25.83 — upside +229%
Expected +88% · Actual -4% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (10 calls matureds) · 📊 on Health : 35.8% · +3.2% (53 calls)
-3.5%
stock -4% · XLV +0%
matured Aug 6, 19
▲ Buy · 🎯$44
Price at call : $37.45 — upside +17%
Today : $25.83 — upside +70%
Expected +17% · Actual +26% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 29% (7 calls matureds) · 📊 on Health : 38.9% · -0.9% (144 calls)
+26.5%
stock +26% · XLV +16%
matured Oct 2, 18
▲ Buy · 🎯$48
Price at call : $38.1 — upside +26%
Today : $25.83 — upside +86%
Expected +26% · Actual +24% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 29% (7 calls matureds) · 📊 on Health : 38.9% · -0.9% (144 calls)
+23.8%
stock +24% · XLV +14%
matured Aug 30, 18
Wedbush 
Mar 22, 17
▲ Outperform · 🎯$89
Price at call : $48.15 — upside +85%
Today : $25.83 — upside +245%
Expected +85% · Actual -34% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (10 calls matureds) · 📊 on Health : 35.8% · +3.2% (53 calls)
-33.5%
stock -34% · XLV +9%
matured Mar 22, 18
▲ Buy
Actual -29% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 29% (7 calls matureds) · 📊 on Health : 38.9% · -0.9% (144 calls)
-29.2%
stock -29% · XLV +14%
matured Feb 22, 18
Jefferies 
Sep 26, 16
▲ Buy · 🎯$60
Price at call : $35 — upside +71%
Today : $25.83 — upside +132%
Expected +71% · Actual +9% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 67% (12 calls matureds) · 📊 on Health : 50% · +9.9% (136 calls)
+9.0%
stock +9% · XLV +12%
matured Sep 26, 17
Wedbush 
Dec 16, 15
▲ Outperform · 🎯$123
Price at call : $72.98 — upside +69%
Today : $25.83 — upside +376%
Expected +69% · Actual -57% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 50% (10 calls matureds) · 📊 on Health : 35.8% · +3.2% (53 calls)
-57.2%
stock -57% · XLV -4%
matured Dec 15, 16
Barclays 
Jul 31, 15
▲ Overweight · 🎯$85
Price at call : $64.42 — upside +32%
Today : $25.83 — upside +229%
Expected +32% · Actual -42% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 8% (12 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-41.7%
stock -42% · XLV -1%
matured Jul 30, 16
Jefferies 
Jul 27, 15
▲ Buy · 🎯$72
Price at call : $59.64 — upside +21%
Today : $25.83 — upside +179%
Expected +21% · Actual -38% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 67% (12 calls matureds) · 📊 on Health : 50% · +9.9% (136 calls)
-38.1%
stock -38% · XLV -1%
matured Jul 26, 16
▲ Buy · 🎯$89
Price at call : $68.81 — upside +29%
Today : $25.83 — upside +245%
Expected +29% · Actual -27% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 29% (7 calls matureds) · 📊 on Health : 38.9% · -0.9% (144 calls)
-26.6%
stock -27% · XLV -3%
matured Apr 30, 16
▲ Buy · 🎯$128
Price at call : $93.94 — upside +36%
Today : $25.83 — upside +396%
Expected +36% · Actual -42% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 29% (7 calls matureds) · 📊 on Health : 38.9% · -0.9% (144 calls)
-41.9%
stock -42% · XLV -6%
matured Mar 2, 16
Barclays 
Mar 2, 15
▲ Overweight · 🎯$127
Price at call : $92.3 — upside +38%
Today : $25.83 — upside +392%
Expected +38% · Actual -45% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 8% (12 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-44.6%
stock -45% · XLV -7%
matured Mar 1, 16
▲ Buy · 🎯$143
Price at call : $114.85 — upside +25%
Today : $25.83 — upside +454%
Expected +25% · Actual -50% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 29% (7 calls matureds) · 📊 on Health : 38.9% · -0.9% (144 calls)
-50.3%
stock -50% · XLV -9%
matured Feb 12, 16
Barclays 
Jan 20, 15
▲ Overweight · 🎯$117
Price at call : $101.92 — upside +15%
Today : $25.83 — upside +353%
Expected +15% · Actual -33% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 8% (12 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-32.6%
stock -33% · XLV -5%
matured Jan 20, 16
Jefferies 
Aug 2, 14
▲ Buy · 🎯$109
Price at call : $95.38 — upside +14%
Today : $25.83 — upside +322%
Expected +14% · Actual -32% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 67% (12 calls matureds) · 📊 on Health : 50% · +9.9% (136 calls)
-32.5%
stock -32% · XLV +25%
matured Aug 2, 15
Barclays 
Jul 17, 14
▲ Overweight · 🎯$107
Price at call : $83.31 — upside +28%
Today : $25.83 — upside +314%
Expected +28% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 8% (12 calls matureds) · 📊 on Health : 37.3% · -8.4% (150 calls)
-25.9%
stock -26% · XLV +27%
matured Jul 17, 15
▲ Buy · 🎯$109
Price at call : $91.01 — upside +20%
Today : $25.83 — upside +322%
Expected +20% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 29% (7 calls matureds) · 📊 on Health : 38.9% · -0.9% (144 calls)
-25.6%
stock -26% · XLV +21%
matured Jun 27, 15
Jefferies 
May 2, 14
▲ Buy · 🎯$86
Price at call : $72.84 — upside +18%
Today : $25.83 — upside +233%
Expected +18% · Actual -8% · Reason (≥ +15%) : ✗ No
🎯 on PCRX : 67% (12 calls matureds) · 📊 on Health : 50% · +9.9% (136 calls)
-8.2%
stock -8% · XLV +27%
matured May 2, 15
Jefferies 
Apr 22, 14
▲ Buy · 🎯$81
Price at call : $71.73 — upside +13%
Today : $25.83 — upside +214%
Expected +13% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 67% (12 calls matureds) · 📊 on Health : 50% · +9.9% (136 calls)
+16.6%
stock +17% · XLV +28%
matured Apr 22, 15
Jefferies 
Apr 21, 14
▲ Buy · 🎯$81
Price at call : $71.73 — upside +13%
Today : $25.83 — upside +214%
Expected +13% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 67% (12 calls matureds) · 📊 on Health : 50% · +9.9% (136 calls)
+16.6%
stock +17% · XLV +28%
matured Apr 21, 15
Jefferies 
Oct 1, 13
▲ Buy · 🎯$58
Price at call : $50.85 — upside +14%
Today : $25.83 — upside +125%
Expected +14% · Actual +88% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 67% (12 calls matureds) · 📊 on Health : 50% · +9.9% (136 calls)
+88.1%
stock +88% · XLV +23%
matured Oct 1, 14
Jefferies 
Mar 11, 13
▲ Buy · 🎯$32
Price at call : $29.28 — upside +9%
Today : $25.83 — upside +24%
Expected +9% · Actual +152% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 67% (12 calls matureds) · 📊 on Health : 50% · +9.9% (136 calls)
+151.7%
stock +152% · XLV +33%
matured Mar 11, 14
Jefferies 
Mar 8, 13
▲ Buy · 🎯$32
Price at call : $29.28 — upside +9%
Today : $25.83 — upside +24%
Expected +9% · Actual +153% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 67% (12 calls matureds) · 📊 on Health : 50% · +9.9% (136 calls)
+153.0%
stock +153% · XLV +33%
matured Mar 8, 14
Wedbush 
Mar 7, 13
▲ Outperform · 🎯$32
Price at call : $28.18 — upside +14%
Today : $25.83 — upside +24%
Expected +14% · Actual +163% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 50% (10 calls matureds) · 📊 on Health : 35.8% · +3.2% (53 calls)
+162.8%
stock +163% · XLV +34%
matured Mar 7, 14
Wedbush 
Sep 11, 12
▲ Outperform · 🎯$23
Price at call : $17.13 — upside +34%
Today : $25.83 — upside -11%
Expected +34% · Actual +123% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 50% (10 calls matureds) · 📊 on Health : 35.8% · +3.2% (53 calls)
+123.1%
stock +123% · XLV +30%
matured Sep 11, 13
Wedbush 
Apr 23, 12
▲ Outperform · 🎯$15
Price at call : $10.14 — upside +48%
Today : $25.83 — upside -42%
Expected +48% · Actual +188% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 50% (10 calls matureds) · 📊 on Health : 35.8% · +3.2% (53 calls)
+188.0%
stock +188% · XLV +28%
matured Apr 23, 13
Wedbush 
Apr 9, 12
▲ Outperform · 🎯$18
Price at call : $10 — upside +80%
Today : $25.83 — upside -30%
Expected +80% · Actual +193% · Reason (≥ +15%) : ✓ Yes
🎯 on PCRX : 50% (10 calls matureds) · 📊 on Health : 35.8% · +3.2% (53 calls)
+192.8%
stock +193% · XLV +29%
matured Apr 9, 13

Frequently asked questions

Should I buy Pacira BioSciences, Inc. stock?

This isn't buy advice. For Pacira BioSciences, Inc., the analyst consensus is "Buy", with an average price target of $29.00 (+12% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Pacira BioSciences, Inc.). We show the numbers — you decide.

Is it too late to buy Pacira BioSciences, Inc.? How high can it go?

The most bullish analyst target on Pacira BioSciences, Inc. is $38.00 (+47% above today's price); the average is $29.00. That's the upside they see. Check how reliable those analysts have actually been on Pacira BioSciences, Inc. on our site before trusting it.

Is Pacira BioSciences, Inc. still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 16 analysts have a real record on Pacira BioSciences, Inc., the best hitting 100% over 2 calls. Current consensus: "Buy". Make your call on data, not noise.

What has Pacira BioSciences, Inc.'s past performance been?

Historical returns and a "how much if I had invested" calculator: PCRX performance & returns.

What is the best month to buy PCRX?

The 12 months ranked by the stock's past returns: best & worst month to buy PCRX.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)